Edgar Filing: CANCER GENETICS, INC - Form 4

Form 4	ENETICS, INC									
May 18, 2015	1	STATES SE				NGE	COMMISSION		PPROVAL 3235-0287	
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er STATEN 5. Filed pur ¹⁵ Section 17(STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							Number: January 31. Expires: 2005 Estimated average burden hours per response 0.5	
(Print or Type R	esponses)									
			2. Issuer Name and Ticker or Trading Symbol CANCER GENETICS, INC [CGIX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) (1 17 NORTH, 2N O CANCER GEI	(Mo ND 05/	Pate of Earliest onth/Day/Year) 14/2015		'n		X Director Officer (give below)	109	6 Owner er (specify	
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
RUTHERFC	ORD, NJ 07070						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Table I - Non	-Derivati	ve Secur	ities Ac	quired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)) Execution Da any	Code	ransactionAcquired (A) or		Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common			Code	V Amo	or		Transaction(s) (Instr. 3 and 4)			
Stock, par value \$0.0001 per share	05/14/2015		А	5,00 (1)) А	\$0	5,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: CANCER GENETICS, INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Derivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) Instr. 3, 4,		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 10.74	05/14/2015		А	10,000	05/14/2016 <u>(2)</u>	05/14/2025	Common Stock, par value \$0.0001 per share	10,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
McLeod Howard 201 ROUTE 17 NORTH, 2ND FLOOR C/O CANCER GENETICS, INC. RUTHERFORD, NJ 07070	Х						
Signatures							
/s/ Howard McLeod by Edward J. Sitar, Attorney in							
Fact		05/14/2015					
** Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The restricted stock underlying the award vests in two equal installments on May 14, 2016 and May 14, 2017, respectively.
- (2) The option vests in two equal installments on May 14, 2016 and May 14, 2017, respectively.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.